2020 Q3 Form 10-Q Financial Statement
#000156459020052197 Filed on November 09, 2020
Income Statement
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| Revenue | $3.461M | $0.00 | $18.00K |
| YoY Change | -100.0% | -95.05% | |
| Cost Of Revenue | $309.0K | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| Gross Profit | $3.152M | $0.00 | $18.00K |
| YoY Change | -100.0% | -60.87% | |
| Gross Profit Margin | 91.07% | 100.0% | |
| Selling, General & Admin | $22.07M | $13.97M | $13.78M |
| YoY Change | 57.95% | 30.07% | 34.92% |
| % of Gross Profit | 700.03% | 76527.78% | |
| Research & Development | $10.21M | $9.481M | $9.996M |
| YoY Change | 7.7% | -0.97% | 20.83% |
| % of Gross Profit | 323.95% | 55533.33% | |
| Depreciation & Amortization | $100.0K | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% | 110.35% |
| % of Gross Profit | 3.17% | 555.56% | |
| Operating Expenses | $32.28M | $23.45M | $23.77M |
| YoY Change | 37.62% | 15.44% | 28.63% |
| Operating Profit | -$29.12M | -$23.45M | -$23.75M |
| YoY Change | 24.18% | 11.21% | 28.85% |
| Interest Expense | $390.0K | $1.260M | $1.340M |
| YoY Change | -69.05% | 125.0% | 226.83% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$80.00K | -$60.00K | -$70.00K |
| YoY Change | 33.33% | ||
| Pretax Income | -$28.82M | -$22.25M | -$22.48M |
| YoY Change | 29.51% | 8.38% | 24.68% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$28.82M | -$22.25M | -$22.48M |
| YoY Change | 29.5% | 8.37% | 24.69% |
| Net Earnings / Revenue | -832.59% | -124872.22% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$1.306M | -$1.064M | -$1.079M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 20.90M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $119.6M | $158.2M | $189.2M |
| YoY Change | -24.4% | 44.47% | 58.83% |
| Cash & Equivalents | $25.79M | $66.15M | $90.42M |
| Short-Term Investments | $95.10M | $92.05M | $98.74M |
| Other Short-Term Assets | $5.500M | $1.700M | $2.000M |
| YoY Change | 223.53% | -10.53% | 66.67% |
| Inventory | $1.346M | ||
| Prepaid Expenses | |||
| Receivables | $2.800M | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $129.3M | $159.9M | $191.2M |
| YoY Change | -19.12% | 43.39% | 58.4% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.725M | $893.0K | $909.0K |
| YoY Change | 93.17% | -10.7% | 29.86% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $5.900M | $63.50M | $43.90M |
| YoY Change | -90.71% | ||
| Other Assets | $300.0K | $2.423M | $2.557M |
| YoY Change | -87.62% | 2323.0% | 2457.0% |
| Total Long-Term Assets | $10.60M | $66.88M | $47.37M |
| YoY Change | -84.15% | 5979.73% | 5821.5% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $129.3M | $159.9M | $191.2M |
| Total Long-Term Assets | $10.60M | $66.88M | $47.37M |
| Total Assets | $139.9M | $226.8M | $238.6M |
| YoY Change | -38.3% | 101.38% | 96.35% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $4.134M | $2.638M | $2.101M |
| YoY Change | 56.71% | -58.13% | -63.14% |
| Accrued Expenses | $13.50M | $11.50M | $9.700M |
| YoY Change | 17.39% | 325.93% | 340.91% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $17.60M | $14.09M | $11.84M |
| YoY Change | 24.93% | 56.53% | 48.05% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $1.700M | $1.700M | $1.900M |
| YoY Change | 0.0% | ||
| Total Long-Term Liabilities | $1.700M | $1.749M | $1.943M |
| YoY Change | -2.8% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $17.60M | $14.09M | $11.84M |
| Total Long-Term Liabilities | $1.700M | $1.749M | $1.943M |
| Total Liabilities | $19.40M | $15.84M | $13.79M |
| YoY Change | 22.5% | 75.97% | 72.34% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$326.0M | -$189.0M | -$166.8M |
| YoY Change | 72.49% | ||
| Common Stock | $57.00K | $57.00K | |
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $120.5M | $210.9M | $224.8M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $139.9M | $226.8M | $238.6M |
| YoY Change | -38.3% | 101.38% | 96.35% |
Cashflow Statement
| Concept | 2020 Q3 | 2019 Q3 | 2019 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$28.82M | -$22.25M | -$22.48M |
| YoY Change | 29.5% | 8.37% | 24.69% |
| Depreciation, Depletion And Amortization | $100.0K | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% | 110.35% |
| Cash From Operating Activities | -$25.08M | -$12.53M | -$14.56M |
| YoY Change | 100.16% | 35.02% | 78.65% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$660.0K | -$50.00K | -$40.00K |
| YoY Change | 1220.0% | -85.29% | -69.23% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $13.90M | -$12.61M | -$142.2M |
| YoY Change | -210.23% | 284200.0% | |
| Cash From Investing Activities | $13.23M | -$12.66M | -$142.2M |
| YoY Change | -204.5% | 3623.53% | 78894.44% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 60.00K | 1.130M | 370.0K |
| YoY Change | -94.69% | -5750.0% | -1950.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -25.08M | -12.53M | -14.56M |
| Cash From Investing Activities | 13.23M | -12.66M | -142.2M |
| Cash From Financing Activities | 60.00K | 1.130M | 370.0K |
| Net Change In Cash | -11.79M | -24.06M | -156.4M |
| YoY Change | -51.0% | 149.59% | 1772.81% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$25.08M | -$12.53M | -$14.56M |
| Capital Expenditures | -$660.0K | -$50.00K | -$40.00K |
| Free Cash Flow | -$24.42M | -$12.48M | -$14.52M |
| YoY Change | 95.67% | 39.6% | 81.05% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
21902000 | ||
| us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | ||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q3 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2020Q3 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
urgn:JelmytoMember | |
| us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
urgn:JelmytoMember | ||
| CY2020Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
22065000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
264000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
202388000 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
11186000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6711000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1585000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
19482000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2604000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
22086000 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21026184 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
21026184 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
57000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
407986000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-228017000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
276000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
180302000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
202388000 | |
| CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10211000 | |
| CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-29124000 | |
| CY2020Q3 | urgn |
Interest And Other Income Expenses Net
InterestAndOtherIncomeExpensesNet
|
308000 | |
| urgn |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
1134000 | ||
| CY2020Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-268000 | |
| CY2020Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.31 | |
| CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22058343 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
142660000 | |
| CY2020Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
188000 | |
| CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6763000 | |
| CY2020Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-268000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
120527000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
224779000 | |
| CY2019Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1124000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7243000 | |
| CY2019Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
22000 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22252000 | |
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
210916000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
180302000 | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
691000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
21499000 | ||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
15777000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
216000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-97958000 | ||
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
120527000 | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3343000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
21902000 | ||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
161447000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
303000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-66173000 | ||
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
210916000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-97958000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-66173000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
295000 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
188000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-386000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
497000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
21499000 | ||
| urgn |
Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
|
620000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-190000 | ||
| urgn |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
736000 | ||
| urgn |
Operating Lease Liability Adjustments
OperatingLeaseLiabilityAdjustments
|
1157000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1346000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2810000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3261000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
520000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2506000 | ||
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
1080000 | ||
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
157000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-84644000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-45017000 | ||
| us-gaap |
Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
|
4000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
29687000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
168852000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
74503000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
14100000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1043000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
133000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
43773000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-154889000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
651000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
3343000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
15853000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
161662000 | ||
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
55000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
16449000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
165005000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-24422000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-34901000 | ||
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
50211000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
101571000 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
25789000 | |
| urgn |
Non Cash New Lease Liabilities
NonCashNewLeaseLiabilities
|
51000 | ||
| urgn |
Non Cash Exercise Of Stock Options
NonCashExerciseOfStockOptions
|
40000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="NOTE_1BUSINESS_NATURE_OPERATIONS" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1-BUSINESS AND NATURE OF OPERATIONS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4<span style="letter-spacing:0.45pt;"> </span>(“UPL”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> wholly owned </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016<span style="letter-spacing:0.45pt;"> </span>(“UPI”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>“Company”)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping and commercializing<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, preparing for the commercial launch of our first commercial product, Jelmyto (mitomycin) for pyelocalyceal solution, formerly known as UGN-101, and its product candidate UGN-102, and raising capital to support and expand these activities. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“LG-UTUC”). Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p> | ||
| urgn |
Entity Incorporation Date Of Incorporation Month And Year
EntityIncorporationDateOfIncorporationMonthAndYear
|
2004-04 | ||
| urgn |
Operations Commenced Date Month And Year
OperationsCommencedDateMonthAndYear
|
2016-02 | ||
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2-BASIS OF PRESENTATION</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (“SEC”) on March 2, 2020.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses since its inception and has an accumulated deficit of $326.0 million and $228.0 million as of September 30, 2020 and December 31, 2019, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it continues its commercial launch of Jelmyto, and expands its portfolio and engages in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on its ability to develop its technologies to the point of FDA approval and subsequent revenue generation and, the Company must raise enough capital to finance these efforts. Based on management’s cash flow projections, the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. However, in the future, the Company may need to raise additional capital to finance the continued operating and capital requirements of the Company. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. If the Company cannot obtain adequate working capital, it may be forced to reevaluate its planned business operations.</p> | ||
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-326000000.0 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-228000000.0 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>most<span style="letter-spacing:0.4pt;"> </span>significant<span style="letter-spacing:0.8pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>relate<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue.</p> | ||
| CY2020Q3 | urgn |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
125500000 | |
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">’</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">’</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p> | ||
| CY2020Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| urgn |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
3466000 | ||
| CY2020Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4134000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4694000 | |
| CY2020Q3 | urgn |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
756000 | |
| CY2019Q4 | urgn |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
399000 | |
| CY2020Q3 | urgn |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
1190000 | |
| CY2019Q4 | urgn |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
2644000 | |
| CY2020Q3 | urgn |
Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
|
1982000 | |
| CY2019Q4 | urgn |
Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
|
2767000 | |
| CY2020Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
430000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
682000 | |
| CY2020Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
8492000 | |
| CY2019Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
11186000 | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1719000 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3610000 | ||
| urgn |
Other Finance Expenses Income
OtherFinanceExpensesIncome
|
-192000 | ||
| urgn |
Other Finance Expenses Income
OtherFinanceExpensesIncome
|
-144000 | ||
| urgn |
Finance Income Expense Net
FinanceIncomeExpenseNet
|
1527000 | ||
| CY2020Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
927000 | |
| CY2020Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
419000 | |
| CY2020Q3 | us-gaap |
Inventory Net
InventoryNet
|
1346000 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | ||
| CY2020Q3 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
103754000 | |
| CY2020Q3 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
492000 | |
| CY2020Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
104246000 | |
| CY2020Q3 | us-gaap |
Interest Receivable
InterestReceivable
|
300000 | |
| CY2020Q3 | urgn |
Debt Securities Available For Sale Unrealized Gain Position
DebtSecuritiesAvailableForSaleUnrealizedGainPosition
|
500000 | |
| CY2020Q3 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
0 | |
| us-gaap |
Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
|
0 | ||
| CY2020Q3 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
98346000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
114386000 | |
| CY2020Q3 | urgn |
Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
|
5900000 | |
| CY2019Q4 | urgn |
Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
|
48556000 | |
| CY2020Q3 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
104246000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
162942000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y8M1D | ||
| CY2020Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3016000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1975000 | |
| CY2020Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1291000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
998000 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1725000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
977000 | |
| CY2020Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
100000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
300000 | ||
| CY2019Q3 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
100000 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
200000 | ||
| us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022. | ||
| CY2020Q3 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P3Y | |
| urgn |
Lessee Operating Lease Extended Lease Expiration Date Month And Year
LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear
|
2022-08 | ||
| CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
424000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1282000 | ||
| CY2020Q3 | us-gaap |
Sublease Income
SubleaseIncome
|
56000 | |
| us-gaap |
Sublease Income
SubleaseIncome
|
168000 | ||
| CY2020Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
28000 | |
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
114000 | ||
| CY2020Q3 | us-gaap |
Lease Cost
LeaseCost
|
396000 | |
| us-gaap |
Lease Cost
LeaseCost
|
1228000 | ||
| CY2020Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2652000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1748000 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1335000 | |
| us-gaap |
Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
|
0 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1306000 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
135000 | ||
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y4M24D | |
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0542 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received Remainder Of Fiscal Year
LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear
|
57000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received Next Twelve Months
LesseeOperatingSubLeasePaymentsToBeReceivedNextTwelveMonths
|
235000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received Two Years
LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears
|
243000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received Three Years
LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears
|
251000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received Four Years
LesseeOperatingSubLeasePaymentsToBeReceivedFourYears
|
49000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Payments To Be Received
LesseeOperatingSubLeasePaymentsToBeReceived
|
835000 | |
| CY2020Q3 | urgn |
Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
|
56000 | |
| urgn |
Lessee Operating Sub Lease Income From Fixed Lease Payments
LesseeOperatingSubLeaseIncomeFromFixedLeasePayments
|
168000 | ||
| CY2020Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3461000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3833000 | ||
| urgn |
Payment On License Agreement Milestone In Acquired In Process Research And Development Expenses
PaymentOnLicenseAgreementMilestoneInAcquiredInProcessResearchAndDevelopmentExpenses
|
10000000.0 | ||
| CY2020Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000.0 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000.0 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22100000 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22100000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21000000.0 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
21000000.0 | |
| CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6763000 | |
| CY2019Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7243000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
21499000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
21902000 | ||
| CY2020Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
34300000 |
